Matt Karpen brings over 25 years of biopharmaceutical experience to Rein Therapeutics, including various leadership positions in process development, process engineering, technology transfer and new product introduction, cGMP operations and technical support, and clinical and commercial manufacturing of both drug substance and drug product. Most recently, Mr. Karpen was Vice President of Lung Therapeutics (purchased by Aileron Therapeutics in 2023) where he successfully led the continuous supply of IMP through multiple early and mid-stage clinical trials across the pipeline, and redesigned processes to significantly improve yield and robustness while reducing the cost of manufacturing. Prior to this, Mr. Karpen was a senior leader in the process validation strategy group within technical operations at Shire Pharmaceuticals. There he developed and implemented innovative process qualification, characterization and control strategies in support of several orphan drug and breakthrough therapy submissions.

Prior to Shire, Mr. Karpen held various leadership roles at Amgen where he developed and implemented industry-leading strategies for process scale-up and tech transfer, product changeover and new product introduction. At Amgen, Mr. Karpen was part of several successful commercial regulatory submissions. Mr. Karpen began his biopharmaceutical career at Pfizer within the process development organization and performed pilot plant operations, tech transfer and supported the start-up of a cGMP manufacturing facility. Mr. Karpen received his Bachelor of Science in Engineering from the University of Dayton. He is published in BioPharm International and is a co-author on PDA Technical Report 56.